Shares of Auris Medical Holding Ltd (NASDAQ:EARS) traded up 7.9% during mid-day trading on Friday . The stock traded as high as $1.52 and last traded at $1.50, 390,200 shares were traded during trading. An increase of 158% from the average session volume of 151,135 shares. The stock had previously closed at $1.39.
Several equities analysts have issued reports on the company. Zacks Investment Research raised Auris Medical from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 22nd. ValuEngine raised Auris Medical from a “hold” rating to a “buy” rating in a report on Wednesday, October 2nd.
The stock has a fifty day moving average of $1.84 and a 200-day moving average of $2.64. The stock has a market cap of $2.64 million, a PE ratio of -0.10 and a beta of -0.51.
About Auris Medical (NASDAQ:EARS)
Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss.
Further Reading: Are FAANG stocks a good investment?
Receive News & Ratings for Auris Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical and related companies with MarketBeat.com's FREE daily email newsletter.